Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.

ABSTRACT: Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype-matched drug candidates are often unapproved or off-label, and improving clinical trial access is critical, involving the appropriate timing of CGP tests. To address this issue, we analyzed the previous treatment data for 441 patients from an observational study on CGP tests discussed by the expert panel at Hokkaido University Hospital between August 2019 and May 2021. The median number of previous treatment lines was two; three or more lines accounted for 49%. Information on genotype-matched therapies was provided to 277 (63%). Genotype-matched clinical trials wer

SUBMITTER: Hagio K 

PROVIDER: S-EPMC10394138 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature